Biocon Biologics Introduces Key C-Suite Executives
Rhonda Duffy was named Chief Operating Officer (COO) and Sandeep Athalye was named Chief Development Officer (CDO) by Biocon Biologics Ltd on August 4.
The company, which is a subsidiary of Biocon Ltd, also announced the appointment of David Gibson as Global Head - Business Development, who will oversee all licencing, strategic partnering, and business development activities. He was previously with GlaxoSmithKline (GSK).
Duffy will be in charge of manufacturing, quality control, and supply chain management. According to the company, she has over 30 years of experience in the global pharmaceuticals industry.
Athalye, who has been with Biocon Biologics for over six years as its Chief Medical Officer, has been promoted to Chief Development Officer to oversee CMC, clinical development, and medical and regulatory affairs, according to the company.
"These new additions to the leadership team bring rich, global experience that will help prepare the organisation for the future and ensure a seamless integration of the recently acquired global biosimilars business from Viatris," said Shreehas Tambe, CEO and Managing Director of Biocon Biologics.
Stephanie Wasco has also been named Head of Communications - Advanced Markets, where she will oversee corporate and marketing communications as well as product branding in advanced markets such as the United States and Europe.